EO9 (Apaziquone): from the clinic to the laboratory and back again
about
Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugsProgress toward overcoming hypoxia-induced resistance to solid tumor therapyAnticancer Activity of Apaziquone in Oral Cancer Cells and Xenograft Model: Implications for Oral Cancer TherapyABC transporters in CSCs membranes as a novel target for treating tumor relapse.Antitumour indolequinones: synthesis and activity against human pancreatic cancer cellsThe Ontogeny and Population Variability of Human Hepatic NADPH Dehydrogenase Quinone Oxido-Reductase 1 (NQO1)Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia.Expression of NAD(P)H quinone dehydrogenase 1 (NQO1) is increased in the endometrium of women with endometrial cancer and women with polycystic ovary syndrome.Efficacy, pharmacokinetic and pharmacodynamic evaluation of apaziquone in the treatment of non-muscle invasive bladder cancer.Hypoxia-Sensitive Materials for Biomedical Applications.Azoreductases in drug metabolism.Preclinical Benefit of Hypoxia-Activated Intra-arterial Therapy with Evofosfamide in Liver Cancer.The efficacy of Apaziquone in the treatment of bladder cancer.Combined molecular modelling and 3D-QSAR study for understanding the inhibition of NQO1 by heterocyclic quinone derivatives.Detection of DT-diaphorase Enzyme with a ParaCEST MRI Contrast Agent.Metal-free nitrative cyclization of N-aryl imines with tert-butyl nitrite: dehydrogenative access to 3-nitroindoles.
P2860
Q26774750-C9712145-B289-44D6-9D91-608C166FBBDDQ26796405-76D26B43-451B-4C3C-BBF9-7D08B4031C05Q28546757-E25B59F2-FD6E-4F0E-89B7-9B393951EB9EQ33879326-B2DFC039-9C6A-490F-85DE-8DFD7E4CF22BQ35831668-8DE219D2-BA9F-4298-B822-ED952BA9E974Q37062619-AA7D9579-62EB-4FB8-962F-08764F5CFE37Q38120850-FD00882B-4E0A-4C9E-BB1F-0695566C3C99Q38658315-A52DFE24-D160-4319-8D06-17D5F66EB5EEQ38668376-C4872524-AF99-45DB-8D40-5D5B39AC87DFQ38754932-B6D7C671-6EFF-4AD6-B566-C4D99020F4B6Q38917152-428D8DB8-7B9A-4FDE-B44B-7C56CB01A463Q46013875-E29E9DEE-B88A-487D-8A59-3CAB2898949DQ47789499-515AA399-E2FE-4482-88B4-0BAB4493CCB4Q48232132-D1561D25-5D1B-4F8F-AE15-7AF168894536Q48331849-CBD209B7-1F5C-4A0B-B7AA-893D36CCC7E0Q53356046-1B9174BE-FA81-4FD8-9B55-E091DC05450F
P2860
EO9 (Apaziquone): from the clinic to the laboratory and back again
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
EO9 (Apaziquone): from the clinic to the laboratory and back again
@ast
EO9 (Apaziquone): from the clinic to the laboratory and back again
@en
type
label
EO9 (Apaziquone): from the clinic to the laboratory and back again
@ast
EO9 (Apaziquone): from the clinic to the laboratory and back again
@en
prefLabel
EO9 (Apaziquone): from the clinic to the laboratory and back again
@ast
EO9 (Apaziquone): from the clinic to the laboratory and back again
@en
P2093
P2860
P1476
EO9 (Apaziquone): from the clinic to the laboratory and back again
@en
P2093
EORTC-Pharmacology and Molecular Mechanism Group
Godefridus J Peters
Hans R Hendriks
Roger M Phillips
P2860
P356
10.1111/J.1476-5381.2012.01996.X
P407
P577
2013-01-01T00:00:00Z